NTRK fusion-positive cancers and TRK inhibitor therapy
N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
[HTML][HTML] Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy
SJ Hsiao, A Zehir, AN Sireci, DL Aisner - The Journal of Molecular …, 2019 - Elsevier
Chromosomal rearrangements involving the NTRK1, NTRK2, and NTRK3 genes (NTRK
genes), which encode the high-affinity nerve growth factor receptor (TRKA), brain-derived …
genes), which encode the high-affinity nerve growth factor receptor (TRKA), brain-derived …
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells
To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …
NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance
F Liu, Y Wei, H Zhang, J Jiang, P Zhang… - Frontiers in oncology, 2022 - frontiersin.org
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
Trial watch: dendritic cell vaccination for cancer immunotherapy
J Sprooten, J Ceusters, A Coosemans… - …, 2019 - Taylor & Francis
Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …
Genomic subtyping and therapeutic targeting of acute erythroleukemia
Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis,
with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid …
with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid …
Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology
RS Go, E Jacobsen, R Baiocchi, I Buhtoiarov… - Journal of the National …, 2021 - jnccn.org
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …
TRK fusion cancers in children: a clinical review and recommendations for screening
CM Albert, JL Davis, N Federman… - Journal of Clinical …, 2019 - ascopubs.org
Chromosomal translocations involving the NTRK1, NTRK2, and NTRK3 genes (TRK
fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC …
fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC …
N-of-1 trials in cancer drug development
The current approaches for cancer drug development lag behind an accelerated need in the
field for a fast and efficient method for evaluating drugs in the personalized medicine era. In …
field for a fast and efficient method for evaluating drugs in the personalized medicine era. In …
Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer
TW Laetsch, DS Hong - Clinical Cancer Research, 2021 - AACR
Chromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions)
have been clinically validated as oncogenic drivers in a wide range of human cancers …
have been clinically validated as oncogenic drivers in a wide range of human cancers …